Summary by Moomoo AI
On January 26, 2024, Evelo Biosciences, Inc. held a special meeting of stockholders where two key proposals were voted upon. The first proposal, which passed with 11,168,514 votes for, 222,299 against, and 7,940 abstained, was the approval of the liquidation and dissolution of the company and the Plan of Liquidation and Dissolution. The second proposal, which also passed, granted discretionary authority to adjourn the special meeting to solicit additional proxies if necessary. However, adjournment was not required as the first proposal received sufficient votes for approval. The Board of Directors now has the authority to proceed with the dissolution but retains the discretion to decide the timing and whether to move forward with or abandon the dissolution, or to amend the plan as permitted by Delaware law without further stockholder approval. This follows the delisting of Evelo Biosciences' shares from Nasdaq, as reported in a previous Form 8-K filed on November 21, 2023.